Abstract: Objective MET exon 14 skipping was a rare driver gene in lung cancer. Efficacy of targeted therapy had been observed in clinical trials. However, few reports were about analyses of patients in the real world. This study was designed to explore the clinical characteristics and outcomes of such patients in the real world. Methods MET exon 14 skipped locally advanced or metastatic non-small cell lung cancer （NSCLC） patients who did not meet the criteria or reject to participate in clinical trials were retrospectively collected, clinicopathologic and molecular characteristics were summarized, objective response and survival analysis were performed. Results Fifteen patients were included in this study. The most common concurrent altered genes were TP53 （53.8%）, MYC （23.1%） and ATM （23.1%）. High programmed death ligand 1 （PD-L1） expression （≥ 50%） was seen in most patients （70.0%, 7/10）. Thirteen patients received bozitinib or crizotinib treatment. Of the 12 evaluable patients, the median progression free survival （mPFS） was 6.1 months while the median overall survival （mOS） was 17.3 months, and the objective response rate （ORR） was 33.3%. Patients with a performance status （PS） score of 1 had a significantly better outcome than those with a poor PS score （>1） （mPFS: 7.3 m vs. 0.4 m, P=0.002; mOS: 21.2 m vs. 9.3 m, P=0.000）. Conclusions The efficacy of targeted therapy for NSCLC with MET exon 14 skipping in this study were worse than published data of clinical trials, which may be related to poor performance status or primary drug resistance.